BUDESONIDE WITH FORMOTEROL

Brand name:

• Symbicort® Turbuhaler® 200/6; Symbicort® Rapihaler® 100/3

Pharmaceutical company:

AstraZeneca Pty Ltd

Condition/indication:
(therapeutic use)

• Asthma

PBAC Submission type:

New listing (Minor)

Comment:

--

Public Summary Document:

PBAC Public Summary Documents - November 2019

Related medicines:

• BUDESONIDE WITH FORMOTEROL

Submission received for:

November 2019 PBAC meeting

Opportunity for consumer comment:

Open 28/08/2019 and close 09/10/2019 (see PBS Website)

PBAC meeting:

Held on 06/11/2019

PBAC outcome published:

Recommended (see PBAC Outcomes)

Notice of intent submitted:

10/02/2020

Lodgement of required documentation:

03/03/2020

Acceptance of complete documentation:

Accepted

Agreement to listing arrangements:

Commenced on 14/04/2020

Status:

Finalised

Government processes:

Commenced on 15/04/2020

Medicine listed on the PBS:

01/06/2020 (see PBS schedule)

---